Clinical Trial Update: A Study to Compare the Conversion to Prograf® (Tacrolimus) to the Continuation of Cyclosporine in Patients at Risk for Chronic Renal Allograft Failure [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial compares conversion to tacrolimus (Prograf) versus continuation of cyclosporine in kidney transplant patients at risk for chronic allog…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Allograft Rejection

Drugs mentioned

• CYCLOSPORINE (cyclosporine)
• Prograf (Tacrolimus)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Graft Rejection, Kidney Transplantation | Phase 4 | Status: COMPLETED